FR-BT-0002

Epigenetic Reprogramming — Biological Age Reversal Without Identity Loss

Epigenetic reprogramming can reverse biological age in living organisms without loss of cellular identity.

EscalatingVS-02·since 2026-09-24

Assessment trajectory

Escalatingstate held · last assessed 2026-09-24

Verification Matrix

Verification position derived from the record’s assessments; dates show when Faultline first recorded each stage.

VS-01

Assertion

—

VS-02

Published evidence

Current from 2026-08-29 — present

VS-03

Audit

First recorded 2024-01-15

VS-04

Replication

—

VS-05

Operation

—

Stage first recorded Current verification position Not yet recorded

State Warrant

Current stateEscalatingVS-02

Why this state?Corrective assessment appended following LPR-001-D26. AS-001 through AS-003 are preserved as dated historical assessments. No post-record scientific result was admitted through this provenance repair.

Assessment summaryLPR-001-D26 narrows the historical evidentiary warrant. The 2006 four-factor iPSC result established pluripotency, while later in-vitro work measured a falling epigenetic clock; those are distinct observations. Altos Labs' capital commitment is institutional context, not efficacy evidence. Clock analyses identify measurement uncertainty, and the 2024 NHP bridge rests on one company-reported ocular injury model rather than multiple published systemic age-reversal studies. Mouse studies remain the strongest functional evidence; ER-100 has entered human dosing but has reported no human outcome results. The claim remains unconfirmed and the measurement and safety questions remain open. ESCALATING / VS-02 is retained on this narrower warrant.

State entered2024-01-15

Last reaffirmed2026-09-24

Mechanisms

Causal mechanisms recorded for this claim. The State Warrant above remains the authoritative current assessment.

Resistance MechanismRM-001

Safety window for partial reprogramming in humans. Sustained or excessive reprogramming can cause dedifferentiation and tumour risks; limited induction seeks to avoid these outcomes. Mouse work and company-reported NHP ocular data do not define long-term safety at clinically relevant human doses. ER-100 has now received IND clearance and entered Phase 1 dosing, so the earlier prediction that human exposure cannot begin is superseded. Whether partial OSK treatment preserves identity and avoids adverse effects in humans remains unreported and requires trial follow-up.

BottleneckBN-001

Biological age measurement validity. The claim requires that biological age be reversed. The primary measurement tool — epigenetic clocks — is contested as a surrogate for genuine rejuvenation. Clocks can be reset by interventions that may not produce functional benefit. If clock reversal and functional rejuvenation are dissociable — if the clock can be moved without changing organismal biology in ways that matter — then the claim's satisfaction conditions are ambiguous. This is a measurement validity bottleneck: the claim cannot be confirmed or contested cleanly until the relationship between clock readings and functional outcomes is established. This is structurally distinct from FR-BT-0001's lexical bottleneck ("meaningfully extend"): that was a threshold dispute; this is a measurement validity dispute. Both are bottlenecks from absence of an agreed measurement framework, as the verdict on FR-BT-0001 observed.

AttractorAT-001

First human safety data and validated functional outcome biomarkers. Two developments would materially advance this record: first, Phase I human trials demonstrating safe OSKM induction at partial reprogramming doses with measurable epigenetic clock reversal and no adverse dedifferentiation signals; second, validated functional outcome biomarkers that correlate with clock reversal and demonstrate that clock reduction predicts downstream health benefits. The first would open the human evidence path; the second would resolve BN-001. Neither is present; both are on active development timelines in the field.

Assessment History

2024-01-15

Initial assessment — Escalating

The claim has not been satisfied in humans. Partial epigenetic reprogramming without loss of cellular identity has been demonstrated in multiple mouse models and is extending toward non-human primates. No human clinical trials have been initiated. The biological mechanism is well-established: OSKM and related factors can reset epigenetic age marks; partial expression can do so without completing dedifferentiation; and the process produces functional improvements in at least some mouse tissues. The claim's human clinical evidence gap remains complete: no partial reprogramming therapy has yet entered a human trial. The pressure state is ESCALATING: the mechanism is well established across multiple mouse models and the field is heavily capitalised (INST-003), but whether partial reprogramming is safe and effective in humans — and whether epigenetic clock reversal constitutes genuine rejuvenation rather than a movable measurement (BN-001) — remains entirely untested outside model organisms.

Verification Stage: VS-03 after ratified review (stored code VS-02 preserved).^*

2026-06-29

Reassessed, no change — Escalating

The human clinical evidence gap that AS-001 identified as complete is now closing. Life Biosciences has received FDA IND clearance for ER-100, a partial OSK reprogramming therapy, with a stated trial start of Q1 2026 — the first human trial of any partial epigenetic reprogramming therapy. This is the first half of AT-001's named resolution attractor ("first human safety data and validated functional outcome biomarkers"); the second half — actual safety and clock-reversal data — does not yet exist, since the trial has only just been cleared to begin, not completed or reported. The pressure state remains ESCALATING rather than moving to RESOLVING: clearance to run a trial is a regulatory and operational milestone, not efficacy or safety evidence. BN-001 (clock validity as a rejuvenation surrogate) is unaffected by this development and remains the record's primary interior bottleneck regardless of how the ER-100 trial proceeds. This assessment exists to record that the record's own named attractor condition has begun to materialise, not to anticipate its outcome.

Sourced from: Life Biosciences public statements and lifespan.io coverage of the FDA IND clearance for ER-100 (reported Feb 2026). Accessed via secondary reporting; the FDA clearance itself and Life Biosciences' own trial registration were not independently verified at primary source. Given this is presented as a significant evidentiary development, primary verification (e.g. via ClinicalTrials.gov registration) is recommended before this assessment is treated as fully confirmed.

Verification Stage: VS-03 after ratified review (stored code VS-02 preserved).^*

2026-08-29

Reassessed, no change — Escalating

PA-006 provenance-in-review final replication confirms that ER-100 has progressed from regulatory clearance to actual human dosing: Life Biosciences reported the first participant dosed on June 9, 2026, and ClinicalTrials.gov lists NCT07290244 as recruiting. This is a substantive operational advance because the claim is now being tested directly in humans rather than only authorised for testing. It does not yet satisfy AT-001 or the governing claim. No results are posted, so there is still no human evidence establishing safety at partial-reprogramming doses, biological-age reversal, preserved cellular identity, or validated functional rejuvenation. BN-001 therefore remains unresolved. ESCALATING / VS-02 is retained pending human outcome evidence.

PA-006 final replication trial. New evidence provenance captured at admission from Life Biosciences' June 9, 2026 first-patient-dosed announcement and ClinicalTrials.gov NCT07290244. Opportunistic legacy enrichment also verified IN-006 against Life Biosciences' January 28, 2026 IND announcement and the trial registry; no factual correction was required.

2026-09-24

Reassessed, no change — Escalating

LPR-001-D26 narrows the historical evidentiary warrant. The 2006 four-factor iPSC result established pluripotency, while later in-vitro work measured a falling epigenetic clock; those are distinct observations. Altos Labs' capital commitment is institutional context, not efficacy evidence. Clock analyses identify measurement uncertainty, and the 2024 NHP bridge rests on one company-reported ocular injury model rather than multiple published systemic age-reversal studies. Mouse studies remain the strongest functional evidence; ER-100 has entered human dosing but has reported no human outcome results. The claim remains unconfirmed and the measurement and safety questions remain open. ESCALATING / VS-02 is retained on this narrower warrant.

Corrective assessment appended following LPR-001-D26. AS-001 through AS-003 are preserved as dated historical assessments. No post-record scientific result was admitted through this provenance repair.

Claim Lineage

Historical narrative recorded for this claim. It does not override the current State Warrant.

2006

Takahashi and Yamanaka induce pluripotency in mouse fibroblasts with four factors. Their study does not measure an epigenetic clock; later in-vitro work tests how clock readings change during reprogramming.

2016

Cyclic partial reprogramming in progeria mice. Ocampo et al. demonstrate lifespan extension without tumour formation through intermittent OSKM. The claim becomes experimentally tractable. Partial reprogramming as a therapeutic concept enters the field.

2019–21

Epigenetic clock reversal demonstrated in multiple tissues. Lu et al. and others demonstrate partial reprogramming in specific tissues (retina, muscle) with functional benefit in aged mice. The claim's mechanistic basis is substantially established in rodent models.

2022–23

Altos Labs launches with $3 billion committed to cellular rejuvenation research; this is institutional investment, not evidence that the claim has been met.

2024

Clock-model uncertainty and intervention-dependent clock disagreement sharpen the measurement question. Life Biosciences reports NHP ocular-function findings at AAO; the single company-reported disease-model result does not establish systemic age reversal.

2026

ER-100 enters human testing. FDA IND clearance is followed by first-participant dosing in the Phase 1 NCT07290244 trial. Human exposure is now established, but no safety, efficacy, age-reversal, identity-preservation, or functional-outcome results have been reported.

Open Questions

Questions retained in this record. The current State Warrant may have narrowed or reframed earlier questions.

OQ-001

What would make Altos Labs' substantial, but broadly targeted, capital commitment claim-specific anticipatory evidence rather than institutional context? The former fifth-occurrence count is not retained without that showing.

Raised 2024-01-15

OQ-002

The clock validity dispute (INST-004) is structurally similar to the FR-AI-0006 mechanism coherence dispute: both ask whether a measurement tool is tracking the thing it purports to measure. Does this suggest a general phenomenon — measurement validity as a resistance mechanism — or is it specific to certain frontier domains?

Raised 2024-01-15

OQ-003

FR-BT-0001 and FR-BT-0002 are structurally adjacent but not related through evidence or ancestry in the way FR-AM-0001 and FR-AM-0002 were related. They share a programme and a validation constraint but have independent evidence trails. Does programme membership without evidence relationship constitute a weaker or different kind of programme structure than the PROG-AM genetic relationship?

Raised 2024-01-15

OQ-004

ER-100's trial is the first direct test of AT-001's named attractor condition. When (or if) it reports results, should the pressure state move directly to RESOLVING, or does a single trial — likely small, likely focused on safety rather than efficacy at Phase 1 — only partially satisfy an attractor that names both safety data and validated functional biomarkers? The record should decide this before the trial reports, not in reaction to whatever it finds.

Raised 2026-06-29

Mutation Log

Mutation	Date	Field	Prior value	Current value
M-015	2026-09-24	provenance_correction	LPR-001-D26 discrepancies_found / pending	LPR-001-D26 discrepancies_corrected / completed
M-014	2026-09-06	description_restored	Legacy ingestion cutoffs: mechanisms:RM-001, mechanisms:BN-001, mechanisms:AT-001	Source-restored complete descriptions
M-013	2026-08-29	provenance_enriched	IN-006 without structured provenance	IN-006 sources[] added
M-012	2026-08-29	assessment_issued	AS-002	AS-003
M-011	2026-08-29	instance_added	—	IN-007
M-010	2026-07-09	description_reordered	—	DESCRIPTION-REORDERED
M-009	2026-07-08	reference_corrected	—	REFERENCE-CORRECTED
M-008	2026-06-29	open_question_raised	—	OQ-RAISED
M-007	2026-06-29	assessment_issued	AS-001	AS-002
M-006	2026-06-29	instances_logged	—	INSTANCES-LOGGED
M-005	2024-01-15	diagnostic_tendency_confirmed	—	DIAGNOSTIC-TENDENCY-CONFIRMED
M-004	2024-01-15	mechanisms_recorded	—	MECHANISMS-RECORDED
M-003	2024-01-15	assessment_issued	—	ASSESSMENT-ISSUED
M-002	2024-01-15	instances_logged	—	INSTANCES-LOGGED
M-001	2024-01-15	record_created	—	RECORD-CREATED

Evidence Sources

7 instances on recordShow sources ↓Hide ↑

IN-001Yamanaka factors and iPSC reprogramming — the theoretical basis and its limits1. Takahashi and Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell (2006) DOI 10.1016/j.cell.2006.07.024 · Abstract — four-factor induction of pluripotency in mouse fibroblasts; no epigenetic clock measurement2. Olova et al., Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity, Aging Cell (2019) DOI 10.1111/acel.12877 · Results — DNA-methylation-age time course in human fibroblasts and distinct kinetics of somatic identity losssupportive

IN-002Ocampo et al. and cyclic reprogramming — partial reprogramming in mice1. Ocampo et al., In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming, Cell (2016) DOI 10.1016/j.cell.2016.11.052 · Abstract and results — cyclic OSKM in premature-ageing mice2. Lu et al., Reprogramming to recover youthful epigenetic information and restore vision, Nature (2020) DOI 10.1038/s41586-020-2975-4 · Abstract — OSK, mouse retinal ganglion cells, methylation and visual-function findingssupportive

IN-003Altos Labs launch — institutional investment in cellular rejuvenation research1. Altos Labs, launch announcement (19 January 2022) · Launch funding, mission, board leadership and Yamanaka's senior scientific adviser role2. Kyoto University CiRA, Prof. Shinya Yamanaka serves as a senior scientific advisor to Altos Labs (19 January 2022) · Unpaid adviser role and supervision of Japan researchneutral

IN-004Clock validity debate — does epigenetic age reversal reflect genuine rejuvenation?1. Kriukov et al., Epistemic uncertainty challenges aging clock reliability in predicting rejuvenation effects, Aging Cell (2024) DOI 10.1111/acel.14283 · Abstract and reprogramming-dataset analyses — model uncertainty changes interpretation of clock trajectories2. Borrus et al., When to Trust Epigenetic Clocks: Avoiding False Positives in Aging Interventions, bioRxiv preprint (2024) DOI 10.1101/2024.10.22.619720 · Abstract — clock disagreement, reliability and multiple-testing analysis; preprint, not peer reviewed at the timecontesting

IN-005Partial reprogramming in non-human primates — bridging toward human evidence1. Life Biosciences, AAO 2024 announcement of non-human-primate ER-100 studies (21 October 2024) · Company-reported NAION-like NHP model, intravitreal OSK, pattern electroretinogram and axon-density measurespartial

IN-006Life Biosciences (ER-100) — FDA IND clearance, first human partial-reprogramming trial1. Life Biosciences (2026), FDA Clearance of IND Application for ER-100 in Optic Neuropathies · January 28, 2026 announcement; Phase 1 NCT072902442. ClinicalTrials.gov, NCT07290244 — Evaluating ER-100 for Safety in People With Glaucoma or NAION · Study overview and registration datessupportive

IN-007ER-100 enters human dosing — first participant treated in Phase 11. Life Biosciences (2026), First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies · June 9, 2026 announcement2. ClinicalTrials.gov, NCT07290244 — Evaluating ER-100 for Safety in People With Glaucoma or NAION · Recruiting status; Phase 1; sponsor and study overviewsupportive